Early detection

is key

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally.  Using a minimally invasive blood draw, our LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

One in 16 people in the US will be diagnosed with lung cancer in their lifetime—and in many cases when it’s too late. We believe our simple blood test may afford those at risk a much better outcome through early diagnosis.”

Paul Pagano | CEO, LungLife AI

Our purpose
is simple

To Be a Driving Force

in the early detection of lung cancer.

To achieve our purpose, we are

dedicated to working collaboratively

 with scientific and clinical partners.

Our LungLB® Test

is a blood-based tool that has been developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer. The test is performed in our CLIA certified laboratory in Thousand Oaks, California. 

Order a Test
Learn more about


How Our LungLB®'s Test is Saving Lives

Watch Video

Early Detection

Watch Video

Creating a Different Future

Watch Video
1 2 3 6

Featured News

LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.